南京高科(600064.SH):高科新創和新浚一期分別收到法院出具的受理通知書
格隆匯 11 月 25日丨南京高科(600064.SH)公佈,公司全資子公司高科新創和公司作為有限合夥人出資69.65%的新浚一期作為原告,就其與被告房永生、樑錫林、紹興閏康合同糾紛事項,分別於2020年10月21日向上海市第二中級人民法院提交了起訴狀。近日,高科新創和新浚一期分別收到上海市第二中級人民法院出具的(2020)滬02民初233號和(2020)滬02民初234號《受理通知書》,獲悉法院已決定立案審理案件。
為維護自身合法權益,高科新創及新浚一期向上海市第二中級人民法院申請對房永生、樑錫林、紹興閏康資產進行訴前財產保全(參見公司臨2020-044號公告)。根據上海市第二中級人民法院出具的(2020)滬02財保16號、(2020)滬02財保17號《民事裁定書》及《財產保全告知書》,法院已對被告持有的400萬股江蘇碩世生物科技股份有限公司(“江蘇碩世”)股權、5000萬元紹興閏康合夥份額等財產採取了保全措施。
此次訴訟請求(1)依法判令被告房永生、樑錫林、紹興閏康共同向高科新創支付合夥份額回售價款人民幣26870.66萬元,向新浚一期支付合夥份額回售價款人民幣49902.32萬元;
(2)依法判令被告房永生、樑錫林、紹興閏康向高科新創、新浚一期賠償因逾期支付回售價款導致的利息損失;
(3)依法判令紹興閏康協助高科新創、新浚一期分別辦理紹興閏康所持江蘇碩世109.9004萬股、204.0995萬股股份質押登記手續(質押權人分別為高科新創和新浚一期,出質人為紹興閏康);
(4)案件訴訟費均由三被告房永生、樑錫林、紹興閏康共同承擔。
此次訴訟是為了積極保障上市公司相關合法權益,鑑於目前案件尚未開庭審理,公司暫時無法準確判斷對公司本期及期後利潤的具體影響金額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.